Pimozide has been identified as a potential STAT5 inhibitor in BCR–ABL1-positive cells and in an AML mouse model [236]; however, this drug is efficacious at high concentrations and is not potent enough to be considered for clinical application [234]. The gene discussed is ABL1; the disease is acute myeloid leukemia.